TARO PHARMACEUTICAL INDUSTRIES LTD Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2023 12 months to Mar 31, 2023	FY2022 12 months to Mar 31, 2022	FY2021 12 months to Mar 31, 2021	FY2020 12 months to Mar 31, 2020	FY2019 12 months to Mar 31, 2019
Cash flows from operating activities:
Net income (loss)
Adjustments required to reconcile net income (loss) to net cash (used in) provided by operating activities:
Depreciation and amortization
Impairment of long-lived assets
Realized loss on sale of long-lived assets
Change in derivative instruments, net
Effect of exchange differences on intercompany balances
Foreign exchange effect of marketable securities and bank deposits
Adjustments to opening balance sheet (PPA)
Deferred income taxes, net
Decrease (increase) in trade receivables, net
Increase in other receivables, prepaid expenses and other
Increase in inventories, net
Decrease (increase) in income tax receivables
Increase (decrease) in trade payables
(Decrease) increase in other accounts payable and accrued expenses
Increase (decrease) in income tax payables
Expense from amortization of marketable securities bonds, net
Net cash provided by (used in) operating activities
Cash flows from investing activities:
Purchase of property, plant and equipment
Investment in other intangible assets
Proceeds from short-term bank deposits, net
Proceeds from long-term deposits and other assets
Investment in short-term bank deposits, net
Investment in marketable securities
Proceeds from marketable securities
(Investment in) proceeds from sale of long-lived assets
(Investment in) proceeds from acquisitions and sale of long-lived assets
Cash acquired from acquisition

Net cash (used in) provided by investing activities
Cash flows from financing activities:
Repurchase of treasury stock
Dividends paid
Net cash used in financing activities

Effect of exchange rate changes on cash and cash equivalents
(Decrease) Increase in cash and cash equivalents
Cash and cash equivalents at the beginning of the period
Cash and cash equivalents at the end of the period
Supplemental disclosure of cash flow transactions:
Cash paid during the year for:
Income taxes
Cash received during the year for:
Income taxes
Non-cash investing transactions:
Purchase of property, plant and equipment included in accounts payable
Adjustment to purchase price
Investment in intangible assets on credit
Non-cash financing transactions:
Purchase of treasury stock
Purchase of marketable securities

Comments